Close Menu

NEW YORK – Personalis said today that it is engaged in a research collaboration with Sarepta Therapeutics in which it is using its platform to characterize the immune response to certain precision genetic therapeutics.

Financial terms of the deal were not disclosed and Personalis did not name specific drugs or disease areas being studied, but Sarepta describes its pipeline as encompassing a suite of experimental genetic medicines for to treat rare neuromuscular and central nervous system diseases.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.